GATEWAY Phase 2 Study: Short-Term Clinical Trial Opportunity for Adults with EPP

The GATEWAY Phase 2 Study is enrolling adults with Erythropoietic Protoporphyria (EPP) to test a potential new treatment.

Some Details:

  • The study takes place in Phoenix, Arizona

  • Travel, hotel, and meals are covered for you (and a caregiver/travel partner, if wanted)

  • US and international participants welcome

  • 9 Days at the study site + travel days

  • Compensation provided for your time

You may qualify if you:

  • Are 18 or older with a confirmed EPP diagnosis (EPP only)

  • Experience symptoms within 40 minutes of sun exposure (can be on an approved drug, cannot be in another clinical trial)

  • Are a non-smoker or willing to stop 30 days prior to participating in study

  • Other inclusion/exclusion criteria will apply

To learn more: Contact Kristen Wheeden directly through the form below or at 301-461-9889.


Previous
Previous

AHP Interview Study

Next
Next

APOLLO Study for EPP & XLP – Now Recruiting!